Pancreatic Cancer Research

ResearcherTianjin Nankai HospitalActive in the last 2 years

Qi Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5055-3637; OpenAlex author ID A5100360313. Sources: OpenAlex.

Their work

Papers
8 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 8

  1. Neogambogic acid enhances anti-PD-1 immunotherapy efficacy by attenuating suppressive function of MDSCs in pancreatic cancer. Last author DOI 10.1016/j.intimp.2024.112696↗
  2. Oxygen microcapsules improve immune checkpoint blockade by ameliorating hypoxia condition in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bioactmat.2022.05.022↗
  3. Oridonin induces autophagy-mediated cell death in pancreatic cancer by activating the c-Jun N-terminal kinase pathway and inhibiting phosphoinositide 3-kinase … First author DOI 10.21037/atm-21-2630↗
  4. Apolipoprotein A-I Mimetic Peptide L-4F Suppresses Granulocytic-Myeloid-Derived Suppressor Cells in Mouse Pancreatic Cancer. First author DOI 10.3389/fphar.2020.00576↗
  5. The role of 2-arachidonoylglycerol in the regulation of the tumor-immune microenvironment in murine models of pancreatic cancer. Co-author DOI 10.1016/j.biopha.2019.108952↗
  6. Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages. Co-author DOI 10.1038/s41416-019-0595-2↗
  7. Osthole inhibits pancreatic cancer progression by directly exerting negative effects on cancer cells and attenuating tumor-infiltrating M2 macrophages. Co-author DOI 10.1016/j.jphs.2018.07.007↗
  8. Apolipoprotein A-I mimetic peptide 4F suppresses tumor-associated macrophages and pancreatic cancer progression. First author DOI 10.18632/oncotarget.21157↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ximo Wang · 4 shared papers, 2018–2024 · strength 0.51
  2. Botao Wang · 3 shared papers, 2018–2021 · strength 0.32
  3. Jing Xun · 1 shared paper, 2024 · strength 0.19
  4. Chongyang Qiu · 2 shared papers, 2018–2019 · strength 0.17
  5. Lei Yang · 2 shared papers, 2018–2019 · strength 0.17
  6. Meiyu Peng · 2 shared papers, 2017–2020 · strength 0.17
  7. Rongxin Zhang · 2 shared papers, 2017–2020 · strength 0.17
  8. Jiangchao Wu · 1 shared paper, 2023 · strength 0.15
  9. Tingbo Liang · 1 shared paper, 2023 · strength 0.15
  10. Xin Zhao · 1 shared paper, 2021 · strength 0.15
  11. Shukun Zhang · 1 shared paper, 2019 · strength 0.09
  12. Lihua Cui · 1 shared paper, 2019 · strength 0.09
  13. Xiaowei Dang · 1 shared paper, 2019 · strength 0.08
  14. Qi Chen · 1 shared paper, 2019 · strength 0.08
  15. Tao Wei · 1 shared paper, 2019 · strength 0.08
  16. Mao Ye · 1 shared paper, 2019 · strength 0.08
  17. Qihan Fu · 1 shared paper, 2019 · strength 0.08
  18. Xiaozhen Zhang · 1 shared paper, 2019 · strength 0.08
  19. Tingbo Liang · 1 shared paper, 2019 · strength 0.08
  20. Xueli Bai · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.